Availability of antimicrobials in a university hospital complex in southeastern Brazil
DOI:
https://doi.org/10.30968/jhphs.2025.162.1257Abstract
Objective: This study aimed to determine the profile of antimicrobials available in a university hospital complex in southeastern Brazil . Methods: Drug utilization study. Antimicrobials available in clinical practice were identified by researching the Anatomical Therapeutic Chemical (ATC) classification system, The new antimicrobials were identified through research Food and Drug Administration, the European Medicines Agency and the Brazilian National Health Surveillance Agency (ANVISA). The antimicrobials available at the university hospital complex were identified by consulting the hospital drug formulary. Antibacterials were classified according to the WHO AWaRE system. Forgotten antibiotics, defined as old antibiotics, often without patent, used in specific indications that provide treatment for infections of multi-resistant bacteria were identified. Results: A total of 301 antimicrobials for systemic use were identified, 20 antifungals, 43 antivirals and 238 antibacterials, 46.2% registered in Brazil and 19.6% available at the university hospital complex. Among antibacterials, 37 were classified as forgotten antibiotics and 21 as new antibacterials. Regarding the ATC classification the available medications were from the following groups: Antibacterials for systemic use (76.3%), followed by antifungals for systemic use (18.6%) and Antivirals for systemic use (5.1%). According to the WHO AWaRE, 21 of the 45 antibacterials available were in the Access group (46.7%), 17 (37.8%) in the Watch group, and 7 (15.5%) in the Reserve group. Concerning the 21 new antimicrobials agents, seven are registered in Brazil and belongs to the Reserve group of AWaRE classification. Conclusion: The antimicrobials available at the university hospital complex are predominantly antibacterials belonging to the Access group of the AWaRE classification, as well as several forgotten antibiotics. Antibacterials needed to treat infections caused by multidrug-resistant bacteria are also available. antifungals from different therapeutic classes are also available, but the number of antivirals is low. The incorporation of new antimicrobials into the drug formulary of the university hospital complex was reduced.
Downloads
References
World Health Organization. Antimicrobial resistance. Available from: https://www.who.int/health-topics/antimicrobialresistance. Accessed Apr 26, 2025.
Kinch MS, Kraft Z, Schwartz T. Antibiotic Development: Lessons from the Past and Future Opportunities. Pharm Res. 2024;41(5):839-848. doi:10.1007/s11095-024-03694-2
Anhøj J, Boel J, Olesen BR, et al. Analysis of antibiotic use patterns in Danish hospitals 2015-2021 using an adapted version of the who aware classification. BMJ Open Qual. 2022;11(4):e002098. doi:10.1136/bmjoq-2022-002098
Kållberg C, Årdal C, Salvesen Blix H, et al. Introduction and geographic availability of new antibiotics approved between 1999 and 2014. PLoS One. 2018;13(10):e0205166. doi:10.1371/journal.pone.02051665.
Ren M, So AD, Chandy SJ, et al. Equitable Access to Antibiotics: A Core Element and Shared Global Responsibility for Pandemic Preparedness and Response. J Law Med Ethics. 2022;50(S2):34-39. doi:10.1017/jme.2022.776.
Organised by: European Observatory on Health Systems and Policies; Chair persons: Dimitra Panteli (Belgium), Elias Mossialos (UK). 10.B. Workshop: Combatting AMR: European collaboration to ensure sustained access to effective antibiotics. Eur J Public Health. 2023;33(Suppl 2):ckad160.639. doi:10.1093/eurpub/ckad160.639
Schulz LT, Kim SY, Hartsell A, Rose WE. Antimicrobial stewardship during a time of rapid antimicrobial development: Potential impact on industry for future investment. Diagn Microbiol Infect Dis. 2019;95(3):114857. doi:10.1016/j.diagmicrobio.2019.06.009.
Sati H, Carrara E, Savoldi A, et al. The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. Lancet Infect Dis. doi:10.1016/S1473-3099(25)00118-5
World Health Organization. WHO fungal priority pathogens list to guide research, development and public health action. World Health Organization; 2022 . Available from: https://www.who.int/publications/i/item/9789240060241 Accessed Apr 26, 2025.
Tängdén T, Pulcini C, Aagaard H, et al. Unavailability of old antibiotics threatens effective treatment for common bacterial infections. Lancet Infect Dis. 2018;18(3):242-244. doi:10.1016/S1473-3099(18)30075-6
WHO. The WHO AWaRE (Access, Watch, Reserve) antibiotic book. Geneva: World Health Organization; 2022.
Tebano G, Li G, Beovic B, et al. Essential and forgotten antibiotics: An inventory in low- and middle-income countries. Int J Antimicrob Agents. 2019;54(3):273-282. doi:10.1016/j.ijantimicag.2019.06.017
Pulcini C, Mohrs S, Beovic B, et al. Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. Int J Antimicrob Agents. 2017;49(1):98-101. doi:10.1016/j.ijantimicag.2016.09.029
World Health Organization. Global action plan on antimicrobial resistance. Geneva: WHO;2015.
Sulis G, Sayood S, Katukoori S, et al. Exposure to World Health Organization’s AWaRe antibiotics and isolation of multidrug resistant bacteria: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(9):1193-1202. doi:10.1016/j.cmi.2022.03.014
CDC. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta: GA US Department of Health and Human Services;2019.
Pulcini C, Beovic B, Béraud G, et al. Ensuring universal access to old antibiotics: a critical but neglected priority. Clin Microbiol Infect. 2017;23(9):590-592. doi:10.1016/j.cmi.2017.04.026
Ueleres Braga J, Araujo RS, de Souza ASS. The Shortage of Benzathine Penicillin and Its Impact on Congenital Syphilis Incidence: An Ecologic Study in the City of Rio de Janeiro. Clin Infect Dis. 2021;72(5):e79-e87. doi:10.1093/cid/ciaa1716
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. doi:10.1093/cid/ciad428.
Carmo A, Rocha M, Pereirinha P, Tomé R, Costa E. Antifungals: From Pharmacokinetics to Clinical Practice. Antibiotics (Basel). 2023;12(5):884. doi:10.3390/antibiotics12050884.
Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. N Engl J Med. 2018;378(11):1004-1017. doi:10.1056/NEJMoa1710922.
Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. N Engl J Med. 2018;378(11):1004-1017. doi:10.1056/NEJMoa1710922
Sprute R, Duda S, Liekweg A, Simon M, Cornely OA. The silent flucytosine shortage in Europe - not a distant problem. Lancet Reg Health Eur. 2023;30:100658. doi:10.1016/j.lanepe.2023.100658
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323(18):1824-1836. doi:10.1001/jama.2020.6019
Pereira LB, Zanetti MOB, Sponchiado LP, et al. Antibiotic use in Brazilian hospitals in the 21st century: a systematic review. Rev Soc Bras Med Trop. 2021;54:e08612020. doi:10.1590/0037-8682-0861-2020
Bhandari RK, Pandey AK, Malhotra S, et al. Addressing Challenges in Antibiotic Access: Barriers, Implications and Strategies for Solution. Pharmaceut Med. 2024;38(6):387-397. doi:10.1007/s40290-024-00538-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to JHPHS : (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to JHPHS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
